Skip to main content
Premium Trial:

Request an Annual Quote

UBS Initiates Coverage of Bruker With Buy Rating

NEW YORK – UBS on Friday initiated coverage of life science tools firm Bruker with a Buy rating and a price target of $70.

In a research note, analyst John Sourbeer said the bank believed factors including Bruker's increasing exposure to consumables and pharma end markets, as well as funding from the US federal government's CHIPS and Science Act, will drive growth at the company.

Sourbeer cited products including Bruker's MALDI Biotyper and timsTOF mass spectrometry platforms along with investment in proteomics, spatial biology, and molecular diagnostics as drivers of increased consumables revenue, which he said remains below the industry average despite improvements over the last five years.

According to UBS, the MALDI Biotyper had an install base of 4,400 as of 2021, and Bruker continues to sell around 400 to 500 units per year. The timsTOF has an install base of more than 500 instruments.

Sourbeer also noted that Bruker's exposure to biopharma remains below the industry average but is poised to grow due to products including the timsTOF. He said that a third of timsTOF placements have been with biopharma firms or CROs.

More generally, UBS projected that the life science tools market will grow in the high-single digits, "powered by breakout opportunities like proteomics."

In Friday afternoon trade on the Nasdaq, shares of Bruker were up around 2 percent at $57.36.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.